Evaluation of the anticoagulant effect in Teneligliption in type 2 diabetic patients

Evaluation of the anticoagulant effect in Teneligliption in type 2 diabetic patients - Evaluation of the anticoagulant effect in Teneligliption in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011847

Enrollment

Registered

2013-10-01

Start date

2025-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Teneligliptin 20mg/day for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: "1)Type 2 diabetic who is enforcing dietary therapy and an exercise cure " "2)Patient who is not using DPP4 inhibitory drug more than 12 weeks before a medical treatment term opening day (84 days) " 3)Patients with written IC

Exclusion criteria

Exclusion criteria: "1)Type I diabetes, the diabetes which arose according to the obstacle of the pancreas, or secondary diabetes patients (Cushing syndrome, tip hypertrophia, etc.) "2)Patient who corresponds to contraindications with the package leaflet of Teneligliptin "3)Patient with an excessive habitual drinking 4)Pregnant and breast-feeding "5)Patients judged by the research responsibility (assignment) doctor to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
HbA1c, pre- and post-prandial(1,2hours)blood glucose, pre-and post-prandial(1,2hours)lipid, pre-and post-prandial(1,2hours)insulin, pre- and post-prandial(1,2hours)proinsulin, pre- and post-prandial(2hours)PAI-1	—

Countries

Japan

Contacts

Public ContactIkuo Inoue

Saitama Medical University Hospital Dept. of Endocrinology and Diabetology

i1901018@saitama-med.ac.jp049-276-1875

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026